Brief: Unity Biotechnology Announces Additional Data From Phase 1 Study Of Ubx1325 In Advanced Vascular Eye Disease

Unity Biotechnology

14/02/2022 13:56

Feb 14 (Reuters) - UNITY Biotechnology Inc  UBX.O :
    * UNITY BIOTECHNOLOGY ANNOUNCES ADDITIONAL DATA FROM PHASE 1
STUDY
OF UBX1325 IN ADVANCED VASCULAR EYE DISEASE
    * UNITY BIOTECHNOLOGY INC - PHASE 2 CLINICAL STUDIES OF
UBX1325
CURRENTLY ENROLLING PATIENTS WITH DME AND WAMD
    * UNITY BIOTECHNOLOGY INC - UBX1325 WAS WELL TOLERATED
WITHOUT
SIGNS OF INTRAOCULAR INFLAMMATION OR OTHER RELATED OCULAR
ADVERSITIES
    * UNITY BIOTECHNOLOGY- SEES 12-WEEK DATA FROM ONGOING PHASE
2A
STUDY IN DME BY MID-2022 ,16-WEEK DATA FROM ONGOING PHASE 2
STUDY IN WET AMD IN Q4 2022

Source text for Eikon:  ID:nGNX7bhYdN 
Further company coverage:  UBX.O 

 ((Reuters.Briefs@thomsonreuters.com;))